Table 1 Demographics and clinical information for multiple sclerosis patients
Patient number | Age (years) | Sex | Duration of disease (years) | Type | Treatment | ARCS | EDSS |
|---|---|---|---|---|---|---|---|
1 | 21 | F | 9 | RRMS | Natalizumab | 79 | 1.5 |
2 | 38 | F | 2 | RRMS | Interferon beta-1a | 100 | 0 |
3 | 57 | F | 4 | RRMS | Betaferon | 73 | 1.5 |
4 | 36 | F | 11 | RRMS | Natalizumab | 78 | 5.5 |
5 | 46 | F | 21 | RRMS | Natalizumab | 81 | 6.0 |
6 | 62 | F | 17 | RRMS | Nil | 72 | 6.5 |
7 | 40 | F | 16 | RRMS | Natalizumab | 82 | 1.5 |
8 | 51 | F | 26 | RRMS | Nil | 90 | 2.5 |
9 | 40 | F | 13 | RRMS | Natalizumab | 77 | 3.5 |
10 | 31 | F | 9 | RRMS | Natalizumab | 71 | 3.0 |
11 | 50 | F | 28 | RRMS | Nil | 96 | 2.5 |
12 | 36 | F | 4 | RRMS | Natalizumab | 83 | 1.0 |
13 | 46 | F | 4 | RRMS | Fingolimod | 86 | 1.5 |
14 | 59 | F | 22 | RRMS | Fingolimod | 60 | 1.5 |
15 | 36 | F | 4 | RRMS | Interferon beta-1a | 95 | 1.5 |
16 | 62 | F | 25 | RRMS | Glatiramer | 93 | 1.5 |
17 | 47 | F | 14 | RRMS | Betaferon | 92 | 1.0 |
18 | 31 | F | 9 | RRMS | Natalizumab | 79 | 1.5 |
19 | 28 | F | 11 | RRMS | Natalizumab | 93 | 1.5 |
20 | 48 | F | 5 | RRMS | Immunoglobulin | 111 | 3.5 |